Showing results (1291-1300 of 1,308) with videos related to
Sort By:
Pageof 131
Science (New York, N.Y.)|December 14, 2023
HIV vaccines induce CD8+ T cells with low antigen receptor sensitivityStephen A Migueles, Danielle M Nettere, Noah V Gavil, et al.The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.Science Advances|April 16, 2025
Dietary methionine restriction started late in life promotes healthy aging in a sex-specific mannerUlalume Hernández-Arciga, Ceda Stamenkovic, Shweta Yadav, et al.Nature|November 30, 2007
The loss of ions from Venus through the plasma wakeS Barabash, A Fedorov, J J Sauvaud, et al.Lancet (London, England)|July 27, 2018
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H Barouch, Frank L Tomaka, Frank Wegmann, et al.Journal of Virology|May 16, 2014
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trialAndrew J Gartland, Sue Li, John McNevin, et al.Radiology|February 27, 2014
Clinical proton MR spectroscopy in central nervous system disordersGülin Oz, Jeffry R Alger, Peter B Barker, et al.NPJ Breast Cancer|December 2, 2021
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupKhalid El Bairi, Harry R Haynes, Elizabeth Blackley, et al.The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.Pageof 131